Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

British Journal of Rheumatology

Volumn 35, Issue 11, 1996, Pages 1067-1074

  Studnicka Benke, A ^a   Steiner, G ^a,c   Petera, P ^a   Smolen, J S ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Cytokines; IL 6; SLE; TNF receptors; TNF

Indexed keywords

C REACTIVE PROTEIN; DNA ANTIBODY; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AUTOIMMUNITY; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029955420     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Steinberg AD. Concepts of pathogenesis of systemic lupus erythematosus. Clin Immunol Immunopathol 1992;63:19-22.
2. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992;63:10-2.
3. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune diseases. N Engl J Med 1979;301:5-8.
4. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401-6.
5. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988;31:729-35.
6. Ter Borg EJ, Horst G, Limburg PC, Kallenberg GM. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990;82:21-6.
7. Huang YP, Perrin LH, Miescher PA, Zubler RH. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988;141:827-32.
8. Jacob CO, McDevitt HO. Tumor necrosis factor-α in murine 'autoimmune' lupus nephritis. Nature 1988;331:356-8.
9. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and 1L-1 in New Zealand black/white mice: enhanced gene expression and acceleration of renal injury. J Immunol 1989;143:3470-5.
10. Jacob CO, Lewis GD, McDevitt HO. MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: Relevance to the pathogenesis of autoimmune disease. Immunol Res 1991;10:156-68.
11. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-lβ gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988;141:3050-4.
12. Vissers MCM, Fontone JC, Wiggins R, Kunkel SL. Glomerular basement membrane-containing immune complexes stimulate tumor necrosis factor and interleukin-1 production by human monocytes. Am J Pathol 1989;134:1-6.
13. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:146-50.
14. Aderka D, Wysenbeek A, Engelmann H et al. Correlation between serum levels of soluble TNF-R and disease activity in SLE. Arthritis Rheum 1993;36:1111-20.
15. Meijer C, Huysen V, Smeenk RTJ, Swaak AJG. Profiles of cytokines (TNF-α and IL-6) and acute phase proteins (CRP and α1AG) related to the disease course in patients with SLE. Lupus 1993;2:359-65.
16. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable MHC Class II associated differences in production of TNF-α: relevance to genetic predisposition to SLE. Proc Natl Acad Sci USA 1990;87:1233-7.
17. Wilson AG, di Giovine FS, Duff GW. Genetics of tumour necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J Inflammation 1995;45:1-12.
18. Seckinger P, Isaay S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor a inhibitor. J Biol Chem 1989;264:11966-73.
19. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990;172:599-607.
20. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80.
21. Aderka D, Engelmann H, Maor Y, Brakebusch, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
22. Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
23. Roux-Lombard P, Punzi L, Hasler F et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:484-9.
24. Steiner G, Studnicka-Benke A, Witzmann G, Ḧfler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995;22:406-11.
25. Swaak AJ, Van Roogen A, Aarden LA. IL-6 and acute phase proteins in the disease course of patients with SLE. Rheumatol Int 1989;8:263-8.
26. Spronk PE, TerBorg EJ, Limburg PC, Kallenberg CGM. Plasma concentration of IL-6 in systemic lupus erythematosus: an indicator of disease activity? Clin Exp Immunol 1992;90:106-10.
27. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993;20:815-21.
28. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus -a putative role in pathogenesis. J Immunol 1991;147: 117-23.
29. Hirohata S, Miyamoto T. Elevated levels of IL-6 in cerebrospinal fluid from patients with SLE and central nervous system involvement. Arthritis Rheum 1990;33:644-9.
30. Mihara M, Fukui H, Koishihara Y, Saito M, Ohsugi Y. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin 6. Clin Exp Immunol 1990;82:533-7.
31. Kitani A, Hara M, Hirose T et al. Autostimulatory effects of IL-6 on excessive B-cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992;88:75-83.
32. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
33. Bencivelli W, Vitali C, Isenberg DA et al. Disease activity in SLE: report of the consensus study group of the European workshop for rheumatology research. III. Development of a computerized clinical chart and its application in comparison of different indices of disease activity: The European consensus study group for disease activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
34. Roux-Lombard P, Steiner G, Cytokine Consensus Study Group of the European Workshop for Rheumatology Research. Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European workshop for rheumatology research. Clin Exp Rheumatol 1992;10:515-20.
35. Whicher J, Ingham E. Cytokine measurements in body fluids. In: Bienvenu J, Fradelizi D, eds. Cytokines and inflammation. Paris: John Libbey Eurotext, 1991:73-84.
36. Mire-Sluis AR. Cytokines - protein structure and biological activity: A complex relationship with implications for biological assays and standardisation. Biologicals 1993;21:131-44.
37. Girardin E, Roux-Lombard P, Grau GE. Imbalance between TNF and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992;76:20-3.
38. Descamps-Latscha B, Herbelin A, Nguyen AT et al. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 1995;154:882-92.
39. Cope AP, Maini RN. Soluble tumor necrosis factor receptors in arthritis. J Rheumatol 1995;22:382-4.
40. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993;150:4346-53.
41. Cope AP, Aderka D, Wallach D et al. Soluble TNF receptor production by activated lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 1995;84:21-30.
42. Taylor DJ. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994;37:232-5.
43. Cope AP, Gibbons DL, Aderka D et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine 1993;5:205-12.
44. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991;88:9292-6.
45. Bigda J, Beletsky I, Brakebusch C et al. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med 1994;180:445-60.
46. Heinrich PC, Castelli JV, Andus T. IL-6 and the acute phase response. Biochem J 1990;265:621-36.
47. Horii Y, Muraguchi A, Iwano M et al. Involvement of IL-6 in mesangial proliferation in glomerulonephritis. J Immunol 1989;143:3949-55.
48. Finck BK, Chan B, Wofsy D. IL-6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91.
49. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in excessive B cell function in patients with SLE. J Immunol 1993;151:6525-34.
50. 1 mice. Clin Immunol Immunopathol 1991;52:421-34.
51. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W mice. J Exp Med 1994;179:305-10.
52. Adebajo AO. Does tumor necrosis factor protect against lupus in West Africans. Arthritis Rheum 1992;35:839-40.
53. Maini RN, Elliot MJ, Charles PJ, Feldmann M. Immunological intervention reveals reciprocal roles for tumor necrosis factor-α and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunopathol 1994;16:327-36.
54. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996;39:9-22.